Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry
スポンサーリンク
概要
- 論文の詳細を見る
- 2001-08-15
著者
-
Figg W
Clinical Pharmacokinetics Section Medicine Branch National Cancer Institute
-
WOO Eunhee
Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, Center for Cancer Rese
-
FIGG William
Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, Center for Cancer Rese
-
MESSMANN Richard
Division of Cancer Treatment and Diagnosis, National Cancer Institute
-
SAUSVILLE Edward
Division of Cancer Treatment and Diagnosis, National Cancer Institute
-
Figg William
Clinical Pharmacology Program Center For Cancer Research National Cancer Institute
-
Woo Eunhee
Clinical Pharmacokinetics Section Medicine Branch National Cancer Institute
-
Messmann Richard
Division Of Cancer Treatment And Diagnosis National Cancer Institute
-
Sausville Edward
Division Of Cancer Treatment And Diagnosis National Cancer Institute
関連論文
- Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry
- Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry
- Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry
- Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry
- Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry
- Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection
- Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection
- Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection
- Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography
- Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry
- Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection
- Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection